NCT06383780

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

A Randomized, Controlled, Multicenter Clinical Study Comparing the Efficacy of Pembrolizumab in Combination With Nab-TPC Regimen Versus the GP Regimen in the First-Line Treatment of Nasopharyngeal Carcinoma With Bone Metastases.

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: XIANG YANQUN · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis.

Detailed description

This study aims to evaluate the efficacy and safety of the GP regimen combined with Tislelizumab compared to the TPC regimen combined with Tislelizumab in the treatment of advanced first-line bone metastatic nasopharyngeal carcinoma patients in high-risk nasopharyngeal carcinoma areas through a prospective, open-label phase III clinical trial.

Conditions

• Nasopharyngeal Carcinoma

Interventions

Type	Name	Description
DRUG	GP combined with Tislelizumab	Gemcitabine combined with cisplatin regimen combined with Tislelizumab
DRUG	TPC combined with Tislelizumab	cisplatin, nab-paclitaxel and capecitabine regimen combined with Tislelizumab

Timeline

• Start date: 2024-05-15
• Primary completion: 2027-05-15
• Completion: 2029-05-15
• First posted: 2024-04-25
• Last updated: 2024-07-16

Locations

1 site across 1 country: China